T2DM, HbA1C = 7.5% to 10.5%, ≥1-month stable treatment, ≤3 oral antihyperglycemic drugs (metformin, SGLT-2 inhibitors, sulfonylureas), ≥3 months stable treatment, ≥3 months stable body weight, BMI ≥ 25 kg/m2, increased risk of cardiovascular events. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.